Category Research

kidney

Novartis’ Fabhalta® Meets Phase III Goal, Slows Kidney Decline in IgA Nephropathy

Novartis’ Fabhalta® (Iptacopan) Achieves Positive Phase III Results, Marking Major Progress in Slowing Kidney Function Decline in Patients With IgA Nephropathy Novartis announced encouraging final results from its pivotal Phase III APPLAUSE-IgAN clinical trial, evaluating the investigational oral therapy Fabhalta®…

Read MoreNovartis’ Fabhalta® Meets Phase III Goal, Slows Kidney Decline in IgA Nephropathy

Viatris Acquires Aculys Pharma, Securing Pitolisant and Spydia® Rights in Japan & Asia-Pacific

Viatris Expands CNS Portfolio in Japan with Acquisition of Aculys Pharma, Gaining Exclusive Rights to Pitolisant and Spydia® Viatris Inc. (Nasdaq: VTRS), a leading global healthcare company, today announced the successful acquisition of Aculys Pharma, Inc., a clinical-stage biopharmaceutical company…

Read MoreViatris Acquires Aculys Pharma, Securing Pitolisant and Spydia® Rights in Japan & Asia-Pacific

Merck Reports Phase 3 Results for Once-Daily HIV Regimen Doravirine/Islatravir (DOR/ISL)

Merck Presents New Phase 3 Data on Investigational Two-Drug HIV Regimen Doravirine/Islatravir (DOR/ISL) Showing Minimal Impact on Weight, Body Composition, and Lipid Levels Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced new results from its Phase…

Read MoreMerck Reports Phase 3 Results for Once-Daily HIV Regimen Doravirine/Islatravir (DOR/ISL)

Neurology Study Shows 95% Reduction in Mortality with Pyrimidine Nucleos(t)ide Therapy in Patients with TK2 Deficiency

Neurology Publication Demonstrates 95% Reduction in Mortality Risk with Pyrimidine Nucleos(t)ide Therapy in Patients with Thymidine Kinase 2 Deficiency (TK2d) UCB, a global biopharmaceutical company focused on the discovery and development of innovative treatments for serious diseases, today announced the…

Read MoreNeurology Study Shows 95% Reduction in Mortality with Pyrimidine Nucleos(t)ide Therapy in Patients with TK2 Deficiency

Zai Lab to Present Updated Phase 1 Data on DLL3-Targeted ADC ZL-1310 at 2025 AACR-NCI-EORTC Conference

Zai Lab to Present Updated Phase 1 Data on DLL3-Targeted ADC Zocilurtatug Pelitecan (ZL-1310) at the 2025 AACR-NCI-EORTC International Conference Zai Lab Limited announced that new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly…

Read MoreZai Lab to Present Updated Phase 1 Data on DLL3-Targeted ADC ZL-1310 at 2025 AACR-NCI-EORTC Conference